Xceleron provides clinical drug development services using auto-combustion microtracer AMS technology to generate early human ADME data. This enables pharmaceutical and biotech companies to obtain absolute bioavailability, mass balance, metabolite profiling, and metabolite identification, accelerating drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development relies on animal studies to assess drug metabolism and excretion (ADME), which are not always predictive of human responses, potentially leading to late-stage failures and increased costs. High doses of radioactive material are typically required for human ADME studies using conventional methods, limiting their use to later stages of development due to ethical concerns.
Solution
Peregrion provides early-stage human ADME (hADME) data through advanced auto-combustion based microtracer Accelerator Mass Spectrometry (AMS) technology, de-risking and accelerating clinical development. By using microtracer doses of 14C-labeled drugs, Peregrion enables ethical and cost-effective hADME studies much earlier in the drug development process, including Phase 0 and Phase I trials. This approach provides critical insights into drug disposition, metabolite profiles, and absolute bioavailability in humans, reducing reliance on animal data and optimizing clinical trial design. The AMS technology's high sensitivity allows for comprehensive metabolite profiling and identification with minimal radioactivity, supporting regulatory submissions and informed decision-making.
Target Audience
Peregrion serves pharmaceutical and biotech companies seeking to accelerate drug development, reduce costs, and improve decision-making through early access to human ADME data.
Features
- Automated sample combustion technology coupled with Accelerator Mass Spectrometry (AMS) for high-sensitivity analysis of 14C-labeled microtracers
- Human ADME (hADME) studies in early clinical development phases (Phase 0, Phase I, and Phase II)
- Absolute bioavailability, mass balance, metabolite profiling, and metabolite identification services
- UPLC coupled with high-resolution mass spectrometry for metabolite identification
- GLP-compliant laboratory operations
- Microtracer studies using hundred-fold less radioactivity compared to conventional methods
- Support for discharge studies from clinical units
- Services applicable to both small molecules and biologics